Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients

[1]  H. Einsele,et al.  Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. , 2005, Blood.

[2]  L. Staudt,et al.  Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling , 2005 .

[3]  H. Johnsen,et al.  Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. , 2005, Blood.

[4]  N. Kröger,et al.  Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  H. Einsele,et al.  Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. , 2004, Blood.

[6]  J. S. San Miguel,et al.  Chronic but not acute graft‐versus‐host disease improves outcome in multiple myeloma patients after non‐myeloablative allogeneic transplantation , 2003, British journal of haematology.

[7]  M. Gold,et al.  CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-kappa B pathway. , 2002, Journal of immunology.

[8]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[9]  G. Gahrton,et al.  Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres , 2001, British journal of haematology.

[10]  G. Martinelli,et al.  Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Siebert,et al.  High incidence of chromosomal imbalances and gene amplifications in the classical follicular variant of follicle center lymphoma. , 1996, Blood.

[12]  A. Grañena,et al.  Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. , 1991, The New England journal of medicine.

[13]  M. Gobbi,et al.  [Allogeneic bone marrow transplantation in multiple myeloma]. , 1991, Haematologica.

[14]  K. Nilsson,et al.  Establishment and characteristics of two unique cell lines from patients with lymphosarcoma , 1974, International journal of cancer.